Price
No data yet.
Social Signal Score
Analyst Ratings
14 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Margaret Alexander
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 23
- Beta
- 0.24
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- 8.26
Financials
Revenue
$0.00-100.0%Net Income
$-20.78MEBITDA
$-20.44MFree Cash Flow
$-15.88MEPS (diluted)
$-0.10Shares Outstanding (diluted)
203.02M+1963.5%Operating Expenses
$22.36MCash & Debt
$136.60MRevenue by Segment (annual)
$7.25MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $7.25M | $-17.41M | $-0.23 |
| 2024 | $566.0K | $-26.43M | $-0.37 |
| 2023 | $392.0K | $-52.34M | $-0.73 |
| 2022 | $1.50M | $-54.17M | $-0.77 |
| 2021 | $208.38M | $122.83M | $1.78 |
| 2020 | $12.62M | $-81.04M | $-1.39 |
| 2019 | $0.00 | $-60.46M | $-1.54 |
| 2018 | $0.00 | $-51.98M | $-2.11 |
| 2017 | $0.00 | $-64.81M | $-3.35 |
| 2016 | $0.00 | $-22.41M | $-2.28 |
| 2015 | $0.00 | $-13.16M | $-1.36 |
| 2014 | $0.00 | $-447.0K | $-0.09 |
Valuation
OVIDhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (5)
- Newsseekingalpha.com·6d ago·Neutral
Ovid Therapeutics Inc. (OVID) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks Transcript Ovid Therapeutics Inc. ( OVID ) UBS Global Biopharma Conference 2026 November 16, 2026 9:40 AM EST Company Participants Meg Alexander - CEO, President & Director Conference Call Participants Aidan Bracken Presentation Aidan Bracken Good afternoon, everyone. My name is Aidan Bracken.
View source ↗ - Newsglobenewswire.com·12d ago·Neutral
…urities were $161.4 million as of September 30, 2026; expected financial runway into 2029 NEW YORK, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today provided business updates including financial results for the third quarter ended September 30, 2026. “The third quarter was focused on execution toward multiple, near-term clinical milestones a…
View source ↗ - Newszacks.com·96d ago·Positive
What Makes Ovid Therapeutics (OVID) a Strong Momentum Stock: Buy Now? Does Ovid Therapeutics (OVID) have what it takes to be a top stock pick for momentum investors? Let's find out.
View source ↗ - Newszacks.com·101d ago·Neutral
Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates Ovid Therapeutics (OVID) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.06 per share a year ago.
View source ↗ - Newsglobenewswire.com·101d ago·Neutral
Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today provided business updates including financial results for the second quarter ended June 30, 2026.
View source ↗
Earnings
Mon, Mar 15(in 4 months)
Consensus estimate $-0.10 per share
Typical surprise +15.2% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Nov 10$-0.10 vs $-0.08miss
- Thu, Aug 13$-0.08 vs $-0.12beat
- Tue, May 12$-0.12 vs $-0.12beat
- Wed, Mar 18$0.06 vs $-0.10beat
- Wed, Nov 12$-0.17 vs $-0.15miss
- Wed, Aug 13$-0.06 vs $-0.16beat
Estimates and results for OVID via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by OVID officers and directors.
- Bought
- $171k
- Sold
- $72k
5 trades
5 trades
- Alexander Margaret A.sold
- Rona Jeffrey Asold
- Levin Jeremy Mbought
- Levin Jeremy Mbought
- Levin Jeremy Mbought
- Alexander Margaret A.sold
- Rona Jeffrey Asold
- Alexander Margaret A.bought
90 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in OVID.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
